PICASSIDE (8-04.3)
Approved for use through 07/13/2006 (6/04.0)

U.S. Peletra att (1/stekmad Orlocy U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a volution control number

			Applic	Application Number								
			Filing	Filing Date								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				First N	First Named Inventor Hir			oto Ogawa				
				Art Ur	Art Unit							_
(NOUTOF	Subili	ISSION UNUEL 37 CFR	1.33)	Exam	iner Na	me						
				Attorn	ey Doc	ket Number		1669-03700				
				_	· ·							
					U.S.	PATENTS				Remove	1	
			1		S.S.I ATENTO							
Examiner		Patent Number	Kind	Issue E	Date		Patentee of Applicant D			ges,Columns,Lines where elevant Passages or Relevant		
Initial*	No	- dioni rambo	Code ¹		of cited Document			ent	Figures Appear			
	-											
	1											
	Ι'											
W		dd additional U.S. Pate								Add	1	
ir you wisi	n to ac	od additional U.S. Patel								Remove		
	_	,	U.S.P	ATENT	APPLI	CATION P	UBLK	CATIONS		Remove		
Examiner	Cite		Kind	Publica	ation	Name of	Paten	tee or Applicant	Pages	,Columns	Lines where	
Initial*	No	Publication Number	Code ¹	Date			of cited Decument			Relevant Passages or Relevant igures Appear		
				Figures Appear								
	1											
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n informati	on ple	ase click the Add	buttor]	
				FOREIG	GN PAT	ENT DOC	UME	NTS		Remove		
	r Cite							lame of Patentee			lumns,Lines	
Examiner Initial*		Foreign Document Number ³	Country Code ² i		Kind	Publication Date	·· /	Applicant of cited		where Relevant Passages or Relevant		T5
						Dane .	1	Occument		Figures A		
							\top		\neg			
	1	2003-34141	JP			2003-02-0		Kabushiki Kaisha Neokkusu				П
							- ['	Neokkusu				_
_	-		_		-		+		-			-
	2	1-237221	JP			1989-09-2	, I,	Kasai Kogyo Co., L	td			П
	-						.		-			
If you wis	h to ar	dd additional Foreign P	atent Do	cument	ritation	informatio	n nles	se click the Add	hutton	Add	1	

NON-PATENT LITERATURE DOCUMENTS

	Application Number		
NEODWATION DIGGS COURT	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Hiroto	Ogawa
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	1669-03700

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs	
	1	International Search Report for Application No. PCT/JP2004/016320, dated January 21, 2005		

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at Iwen USPTO_GDV or MPEP 901.04. 2 Enter office that issued the document, by the In-clearing code (WIPO Standard ST3.). 3 Fee Implanees patent documents, the advantage on the parent of the Emperor unsprised see sensit number of the patent of the Emperor unsprised seems of the Code (WIPO Standard ST3.16 if possible. 3 Applicant is to place a check mark there if Emplish languages the residence is attached.

Application Number Fling Date Fling Date Fling Date Fling Date Fling Manual Inventor | Heolo Ogawa Art Unit Examiner Name | Ex

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) for the control of the control

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/mwatkins/	Date (YYYY-MM-DD)	2006-05-04
Name/Print	Marcella D. Watkins	Registration Number	36962

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Gad 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1436, Alexandria, V.S. 2213.1-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2213.1-450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.